50 results about "Pulmonary compliance" patented technology

A ventilator for ventilating a patient also assists a clinician in determining a suitable PEEP for the patient. For this purpose, a graph or tabular display of a series of different value PEEPs and corresponding functional residual capacities of the patient may be provided. Or, the relationship between lung compliance and a series of different values of PEEP may be provided. Or, the amount of the lung volume recruited/de-recruited at various levels of PEEP may be determined for use in selecting a desired PEEP. To this end, the functional residual capacity of the lungs is determined for a first PEEP level. The PEEP is then altered to a second level and a spirometry dynostatic curve of lung volume and pressure data is obtained. The lung volume on the dynostatic curve at a lung pressure corresponding to the first PEEP value is obtained. The difference between the functional residual capacity of the lungs at the first PEEP level and that determined from the dynostatic curve represents the lung volume recruited/de-recruited when changing between said first and second PEEPs.

A ventilator for ventilating a patient also assists a clinician in determining a suitable PEEP for the patient. For this purpose, a graph or tabular display of a series of different value PEEPs and corresponding functional residual capacities of the patient may be provided. Or, the relationship between lung compliance and a series of different values of PEEP may be provided. Or, the amount of the lung volume recruited/de-recruited at various levels of PEEP may be determined for use in selecting a desired PEEP. To this end, the functional residual capacity of the lungs is determined for a first PEEP level. The PEEP is then altered to a second level and a spirometry dynostatic curve of lung volume and pressure data is obtained. The lung volume on the dynostatic curve at a lung pressure corresponding to the first PEEP value is obtained. The difference between the functional residual capacity of the lungs at the first PEEP level and that determined from the dynostatic curve represents the lung volume recruited/de-recruited when changing between said first and second PEEPs.

A breathing assistance device is provides guidance to the rescuer, guidance to the victim, and modifies treatment parameters automatically based upon feedback loops relating to patient needs. Guidance can include pictograms showing cartoons of lung expansion, airway patency, breathing rate, and depth of breathing. A microprocessor preferably produces the pictorial guidance as a function of at least one of estimated end tidal CO2, estimated fractional inspired oxygen, estimated fractional expired oxygen, estimated airway resistance, and estimated lung compliance. The microprocessor can also execute a software code that executes a feedback loop that attempts to normalize values of a parameter over time, by controlling at least one pressure in a neck pillow, mask pressure, breathing rate, breathing volume, inspiration time, and expiration time. Contemplated parameters can include estimated end tidal CO2, estimated fractional inspired oxygen, estimated fractional expired oxygen, estimated airway resistance, and estimated lung compliance.

The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and/or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and/or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.

The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and/or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and/or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.

The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and/or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and/or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.

The present invention provides methods and compositions for the treatment of fibrotic conditions, to increase lymphocyte production in vivo, and to improve and/or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and/or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH.

The system and method may measure and monitor physiological changes in a body. In some embodiments, the system and method may measure the impedance at a site in the body. In some embodiments, the system and method identify, quantify, and localize leaks from a site following surgery, measure cardiac contractility, or lung compliance. In an embodiment, the system includes a measuring device with one or more sensors embedded in a porous matrix. Changes in the electrical properties of one or more sensors may be used to determine the presence of leaks from a site following surgery, measure cardiac contractility, or lung compliance, depending on the position of the device.

The present invention offers novel equilibration methods for very high resolution, three-dimensional imaging of imaging of lung compliance and distribution of functional residual capacity (FRC) in the lung using hyperpolarized helium-3 (³He) gas (H³He), and collecting local magnetic resonance image data therefrom. Using the present methods permits many functions that have been performed on a regional level for the whole lung using non-polarized helium, to be calculated for the first time from the local MRI measurements of local H³He, such as measuring volume or compliance.

The invention discloses a medical ventilator and a method of continuously measuring airway resistance and compliance for the medical ventilator. The medical ventilator comprises a pressure control device, the pressure control device is provided with an air source input port, an air flow control port and an air flow output port, and the air flow output port is connected with an air flow sensor and a pressure sensor that measures airway pressure of a patient; the medical ventilator employs an airway positive pressure ventilation mode, a high-frequency oscillatory pressure with adjustable amplitude, frequency and duration is added to the pressure level of the airway positive pressure ventilation mode, airway resistance and lung compliance of the respiratory system are measured through the high-frequency oscillatory pressure and flow, the airway resistance and the lung compliance are continuously monitored, and the medical ventilator and the method are used to measure respiratory resistance and compliance at the premise of not interfering normal respiratory cycle of a patient and provide continuous monitoring for the respiratory resistance and compliance. The medical ventilator and the method will help a doctor to set parameters of a mechanical ventilator such that ventilation state of a patient is adjusted in time and ventilation therapeutic efficiency of the ventilator is improved.

Methods and systems for visualizing mechanical ventilation information are provided. One system includes a user interface for a medical system having a ventilator is provided. The user interface includes a memory storing one or more sensor measurements for a patient and a processor. The processor is programmed to display a visualization of a tidal volume determined from one of the sensor measurements of the patient and display a visualization of lung compliance for the patient, wherein the tidal volume visualization and the lung compliance visualization are displayed concurrently.

The invention relates to a severe respiratory distress syndrome patient prone position support. The severe respiratory distress syndrome patient prone position support comprises a supporting plate, and a left upper base, a right upper base, a left lower base and a right lower base which are fixed on the supporting plate, and is characterized in that the upper part and the lower part of the left upper base and the right upper base are respectively provided with an upper concave cavity and a right-angle groove, the lower part and the upper part of the left and right lower bases are respectivelyprovided with a lower concave cavity and a right-angle groove, the upper concave cavity and the lower concave cavity respectively receive a shoulder and a thigh root of the patient, and the right-angle grooves on the four bases jointly form a circular groove for receiving the belly of the patient. By adopting the prone position support for ventilation provided in the invention, the patient can conveniently and comfortably lie prone on the left and right upper bases in a prone position state, even if the patient has a big belly, due to the receiving of the circular groove for the belly of the patient, the free downward expansion of the lung of the patient in the mechanical ventilation process can also be ensured, the problem of poor lung compliance can be improved, and the severe respiratory distress syndrome can be ensured to be treated effectively in time.

Determining the lung compliance and lung resistance of a subject undergoing respiratory therapy using non-invasive ventilation requires taking the presence of leaks into account. In particular, variable and unintentional leaks at or near a subject interface appliance may be dynamically determined based on an average resistance of the leak orifice of the subject.

The invention provides lung perfusion fluid for perfusing a transplant donor lung and a preparation method for the lung perfusion fluid. The lung perfusion fluid can be used for providing good lung protecting and resuscitating actions and can meet the requirements of the transplant donor lung on perfusion and preservation; meanwhile, the time of perfusion is relatively long, and the donor lung still can retain good lung compliance and oxygenation capability 6 hours after the donor lung is subjected to perfusion by the lung perfusion fluid provided by the invention; and finally, the preparation method for the lung perfusion fluid is simple, and raw materials are readily available and are economical and practical, so that the lung perfusion fluid is suitable for being popularized and applied to general laboratories or hospitals.

Measurement of airway resistance and/or lung compliance during non forced exhalation is performed using initial occlusion of exhalation followed by removal of the occlusion or opening of a shutter. The measurement device can use a single sensor to measure both pressure and flow. A pressure monitor can detect that exhalation is improperly forced to signal an error or to reject a pressure and flow measurement from a forced exhalation trial.

Methods and apparatuses are described for direct rapid measurement of pulmonary flow resistance. A measurement of a first pressure in a gas-tight chamber is received from a pressure sensor when a gas output port of the chamber is closed, a patient is blowing into a gas inlet of the chamber at a given pressure, and a gas-flow path between the inlet and output port has a resistance value. A measurement of a second pressure in the chamber is received from the pressure sensor and a measurement of gas flow through the chamber is received from a gas flow sensor when the output port is opened and the patient is blowing into the inlet to maintain the given pressure relatively constant. A pulmonary flow resistance is computed based upon the measurement of the first pressure, the measurement of the second pressure, the resistance value, and the measurement of gas flow.

The lung compliance of a subject that is at least partially self-ventilating is determined. The quantification of lung compliance may be an estimation, a measurement, and/or an approximate measurement. The quantification of lung compliance may be enhanced over conventional techniques and/or systems for quantifying lung compliance of self-ventilating subjects in the lung compliance may be quantified relatively accurately without an effort belt or other external sensing device that directly measures diaphragmatic muscle pressure, and without requiring the subject to manually control diaphragmatic muscle pressure. Quantification of lung compliance may be a useful tool in evaluating the health of the subject, including detection of fluid retention associated with developing acute congestive heart failure.

The invention discloses a nasal catheter fixation device for use with a neonatal CPAP breathing machine. The device includes a square rod support base, a nasal intubation plate, an air duct pipe, a connecting bar rack, a human-computer interface table, a stand column plate and a liquid oxygen mixing valve seat. Through combination of the nasal intubation plate and the liquid oxygen mixing valve seat, and through treatment with a humidification water tank liquid passage and a pure oxygen storage box air passage utilizing a bent backwashing pipe connector cap of the liquid oxygen mixing valve seat, the retention amount of water vapor in the nasal intubation plate and the air duct pipe is ensured to be lowest, and recoil force allows a rotary sieve to filter condensate of the tidal volume, thus ensuring that water vapor and oxygen are mixed to achieve an oxygen supplementing wetting effect, relieving alveolar intumescence by vapor attachment, adjusting a durable dried situation of the lung passage, making respiratory muscle loose, wet and elastic, promoting increase of the functional residual volume, improving lung compliance, improving respiratory regularity of newborns, and allowingthe device to automatically match with needs of a child's body to achieve micro-adjustment and high oxygen mixing adaptability.

The invention relates to a fully synthetic pulmonary surfactant (PS) preparation as well as a composition, a preparation method and application thereof. Specifically, the invention provides a PS preparation with a brand new formula. The invention also provides a method for preparing the PS preparation. The invention also provides a pharmaceutical composition containing the PS preparation. The PS preparation provided by the invention has the characteristics of high surface activity and lasting drug effect, and has sufficient in-vitro surface tension and animal pharmacodynamic model support. The fully-synthesized PS preparation can obviously improve the in-vitro surface activity, the blood oxygen level, lung compliance and the like of animal pharmacodynamic experiments are obviously improved, and the fully-synthesized PS preparation has a more stable and lasting curative effect. The total synthesis PS preparation can be clinically used for treating and preventing diseases related to pulmonary surfactant deficiency or dysfunction, such as neonatal respiratory distress syndrome NRDS, secondary respiratory distress syndrome ARDS, and PS deficiency or dysfunction induced by severe pneumonia, meconium inhalation syndrome, new crown pneumonia, chronic obstructive pulmonary disease and the like.

A patient simulator system for teaching patient care is provided. The system includes a patient simulator. The patient simulator includes a patient body comprising one or more simulated body portions. The one or more simulated body portions include a lung compliance simulation system in some instances. In that regard, the lung compliance system is configured to be used with an external ventilator, including positive end-expiratory pressure (PEEP) and assisted-control ventilation. In some instances, the lung compliance system includes a lung compartment, a simulated lung positioned within the lung compartment, where the lung compartment defines an available volume for the simulated lung to expand into and where the available volume for the simulated lung to expand into is adjustable to control a compliance of the simulated lung.

Resuscitation and ventilation monitoring devices are provided. A device includes an inlet in fluid communication with airflows exchanged with lungs of a patient and an airflow meter for measuring characteristics of the airflows. A user may provide a controller with patient information, e.g., height, weight, gender, or age, via a measurement selector, enabling the controller to determine acceptableranges of measured airflow characteristics. The device may determine a current mode of ventilation and associated ventilator settings based on the measured airflow characteristics. The device may also identify and filter out artifacts present in the ventilation signal, and determine whether a respiratory failure phenotype is present in the ventilation. If the current mode of ventilation and associated ventilator settings fall outside an acceptable range, the ventilation is classified as off-target and the controller may cause a sensory alarm to alert the user. The device may suggest a corrective action based on the type of off-target ventilation detected. The device may also continuously analyze ventilation to determine changes in lung compliance over time and to identify pathological changes over time. The device may work within a network of devices and user interfaces via wired or wireless communication, and is not restricted to or dependent on the type of ventilatory device with which a patient is being supported.

The invention describes a detection method for determining pulmonary overexpansion by using electrical impedance tomography. The detection method is used for detecting at least one factor causing pulmonary overexpansion based on electrical impedance tomography images. The detection method comprises the following steps of: judging whether an area with pulmonary overexpansion exists in an area of interest or not based on first pulmonary compliance corresponding to first positive end expiratory pressure and second pulmonary compliance corresponding to second positive end expiratory pressure; judging whether pulmonary overexpansion is caused by increase of positive end expiratory pressure or not based on change of gas capacity reference values of actual end expiratory pressure of the second positive end expiratory pressure and the first positive end expiratory pressure and change of gas capacity reference values of end expiratory pressure predicted based on the first pulmonary compliance; and judging whether pulmonary overexpansion is caused by tidal volume or not based on change of actual gas capacity reference values of end inspiratory pressure of the second positive end expiratory pressure and the end expiratory pressure of the first positive end expiratory pressure and change of gas capacity reference values predicted based on the first pulmonary compliance. Therefore, factors causing pulmonary overexpansion can be determined.

The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian alpha- and/or beta-defensin.